Ticker Reports for May 6th
3 Mid-Cap Medical Stocks Outperforming the Market
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance. Investors looking beyond large-cap names may find compelling opportunities in mid-cap stocks that deliver strong growth and defy broader market weakness.
Here are three mid-cap medical stocks that have significantly outperformed the broader market so far this year. Each shows strong momentum, bullish analyst sentiment, and potential for continued upside.
Penumbra: A High-Growth Medical Devices Company Outperforming the Market
Penumbra, Inc. (NYSE: PEN) designs, develops, manufactures, and markets innovative medical devices used in neuro and vascular interventions. With a market capitalization of $11.3 billion, the company has emerged as a standout performer in the medical device space. While recession concerns and geopolitical uncertainty have weighed on equities broadly, Penumbra’s stock is up an impressive 23% year-to-date and 43% over the past 12 months.
The company reported strong first-quarter earnings on April 23, posting earnings per share of $0.83, beating consensus estimates by $0.17. Revenue climbed 16.3% year-over-year to $324.1 million, exceeding expectations of $315.7 million. Despite market volatility in April, Penumbra held its uptrend and trades just 5% below its 52-week high, indicating continued investor confidence.
Valuation remains elevated, with a trailing P/E ratio of 274, though its forward P/E of 58 better reflects its growth trajectory. Analysts remain bullish. Of the 17 analysts covering the stock, the consensus rating is a Moderate Buy, with a price target that points to further potential upside.
TransMedics Group: Momentum and Growth in Organ Transplant Technology
TransMedics Group (NASDAQ: TMDX) is a commercial-stage medical technology company revolutionizing organ transplant procedures. The firm’s flagship product, the Organ Care System (OCS), preserves donor organs in near-physiological conditions, significantly extending the window for transplantation. The company also offers the National OCS Program, a turnkey solution for organ retrieval and logistics.
The stock began to rally in April after breaking out above key resistance around $80. Since then, shares have gained substantial momentum and are now up nearly 48% year-to-date. The stock’s high P/E ratio of 91 may give some investors pause, but its forward P/E of 41 suggests strong earnings growth ahead.
Analysts are optimistic about the company’s outlook. Eleven analysts cover the stock, all contributing to a Moderate Buy consensus rating. The consensus price target implies up to 35% upside from current levels.
One catalyst and factor contributing to the stock's surge and momentum is its high short interest. As of April 15, short interest stood at 28% of the float, about 8.8 million shares. While down 7.3% from the prior month, the elevated level may contribute to a short squeeze dynamic, fueling the rally.
ADMA Biologics: Biotech Strength With Room to Run
ADMA Biologics (NASDAQ: ADMA) is a biopharmaceutical company that develops, manufactures, and markets plasma-derived biologics for treating immune deficiencies and infectious diseases. With a market cap of $5.6 billion, it’s one of the most impressive biotech performers of 2025, with shares up 38% year-to-date.
The stock is trading just 7% below its all-time high, which was reached in late April. Investors will be watching closely as the company is scheduled to report earnings on May 7. ADMA trades at a P/E of 29 and a forward P/E of 23, supported by projected EPS growth of 45% in 2025.
Despite limited analyst coverage, only four analysts cover the stock, all of them rate it as a Buy, reinforcing the stock’s strong growth profile and favorable risk-reward balance.
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks
The market is in freefall—and Trump's new tariffs just lit the fuse.
Millions of investors are blindsided as stocks plunge… but this is only Phase 1.
If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Top 3 Sectors Where Valuations Are Most Below Market Levels
Whether focusing on growth stocks, value stocks, or a mix, the goal is the same: find and invest in undervalued assets. This thread remains true when considering how to invest across the 11 different stock market sectors. At certain times, specific sectors can see their value relative to the overall market trade at a discount.
A way to identify this is by looking at sector-specific forward price-to-earnings (P/E) ratios. As of May 2, according to Yardeni Research, the S&P 500 Index was trading at a forward P/E of just over 20. The analysis below will look at the three sectors trading the furthest below this figure, indicating that these sectors are potentially undervalued.
XLU: Utilities Have Tariff Resistance and Forward P/E Is Down
The first is the S&P 500 utilities sector. The Utilities Select Sector SPDR Fund (NYSEARCA: XLU) tracks it closely. It is trading at a forward P/E of under 18x, which is around 13% below the S&P 500. This comes even as the sector is the best performing so far in 2025, with a total return of approximately 6% as of May 2. Utilities have a key advantage in today’s economy: their concentration in the United States.
The latest FactSet Earnings Insight full report shows that S&P 500 utilities companies earn 98% of their revenues from the United States. This is the highest percentage among all sectors. This means that these companies have to worry much less about the effect of tariffs. Utilities have also impressed in Q1 earnings so far. They posted the largest difference between estimated and actual revenues at almost 4%. Additionally, XLU boasts one of the highest dividend yields among the SPDR sector funds at nearly 2.8%. This can provide a valuable source of stable returns in uncertain times.
XLV: Healthcare Is a Q1 Earnings Standout
Second is the S&P 500 healthcare sector, which is trading at a forward P/E of just under 17x. Technically, the financial services sector is trading at a bigger discount than healthcare, with a forward P/E of just over 16. However, context is vital. The financial services sector usually trades at a forward P/E significantly below the market. Thus, it is difficult to say that the difference today indicates a significant degree of undervaluation. Rather, it seems likely that it is simply a part of the general relationship between financials and the overall market. So, it makes more sense to point to healthcare as being potentially undervalued.
Healthcare has seen extended periods in the past where its forward P/E trades significantly above or in line with that of the overall index. So, it is notable to point out that the sector’s forward P/E ratio is trading almost 17% below that of the S&P 500. Adding to the intrigue is that 90% of healthcare companies in the S&P 500 reported Q1 earnings that were above consensus estimates. This is the highest figure of any sector in Q1. It has also seen 50% of companies issue positive guidance, and 50% issue negative guidance. This stands out positively against most sectors, which have generally seen more companies report negative guidance. The highly liquid Health Care Select Sector SPDR Fund (NYSEARCA: XLV) makes investing in this sector easy.
XLE: Low Forward P/E and Increasing Demand Could Be a Recipe for Success
Last up is the S&P 500 energy sector, which is trading at a forward P/E of 14. This is a substantial discount to the overall market at around 31%. Warren Buffett and his future successor, Greg Abel, discussed the energy and utilities sectors at the Berkshire Hathaway (NYSE: BRK.A) shareholders' meeting. Abel noted that the capital required to meet the long-term projection of energy demand is "enormous." This is particularly true when thinking about data centers. The International Energy Agency (IEA) says that over the next five years, energy demand from data centers will double.
Analysts expect emerging market economies to drive rising energy demand for decades. S&P 500 energy companies can benefit from this, as over a third of their revenues come from outside the United States. According to FactSet, in line with the sector’s low forward P/E ratio, Wall Street price targets indicate a significant upside of 24% in the energy sector. This is the highest percentage of any sector. The Energy Select Sector SPDR Fund (NYSEARCA: XLE) is one of the most-used ETFs for tracking the sector's performance.
Before it hits the headlines: the altcoin that's building quietly
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway.
One altcoin is quietly positioning itself to overthrow the entire banking system.
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
Those subscribing to a momentum investing strategy tend to believe that stocks experiencing price increases tend to rally, so long as both internal and external conditions don't change. Of course, no rally can continue forever, so investors may measure momentum across different timeframes. The key goal for a momentum investor is to identify a possible target and enter a position while there is still potential for upside.
Three stocks across multiple sectors may draw the attention of investors looking for a momentum play based on their share price improvement over short, medium, and long timeframes. These companies may be overlooked by investors more broadly because they are not necessarily the biggest names within their sectors or industries, but they are each supported by several positive analyst ratings.
Online-Focused Beauty Firm Beat Earnings Expectations, Continues to Grow
Oddity Tech Ltd. (NASDAQ: ODD) is a tech company that partners with the beauty and wellness industry to build digital-first brands along with an AI-based online consumer platform. Five out of eight analysts that have rated Oddity have given it a Buy signal.
Oddity shares trended upward throughout most of April, but they spiked in the month's final days after a highly successful first-quarter earnings report. It is up about 70% in the last month and 53% year-to-date (YTD). The company topped analyst expectations for earnings per share (EPS) by six cents, boosted revenue by 27% year-over-year (YOY), reported a strong gross margin of 74.9%, and raised forward guidance.
Often, investors will shy away from a company with a significant share price boost due to a positive earnings report, as these gains can be short-lived. However, Oddity presents numerous signs that these trends could continue. The firm is a leader in the shift toward online shopping in the beauty industry, which appears to be picking up pace.
Its IL MAKIAGE brand is a standout, and the company looks on target to achieve its goal of $1 billion in revenue by 2028. While Oddity is heavily exposed to the U.S. market, and the potential for tariffs that could impact demand and prices, it is rapidly expanding into other areas, particularly in Europe.
Despite Recent Downward Trend, NeoGenomics Builds Momentum With Raised Guidance and Strategic Acquisition
Cancer and cytogenetics testing service provider NeoGenomics Inc. (NASDAQ: NEO) has a Buy rating from five Wall Street analysts and a consensus price target more than 85% above current price levels. This may suggest that the company's recent reversal of a downward trend—it climbed by 22% from April 30 to mid-day on May 5 after falling from a one-year high achieved in January—has the potential to continue.
NeoGenomics' share price drop in late April is likely attributable to the firm's lackluster earnings report, in which losses per share were wider than analysts predicted and revenue missed expectations. Though volatility may be in store for this firm as its clients, which include academic institutions and researchers as well as oncologists and others in the medical field, wrestle with the impacts of canceled research funding, NeoGenomics could fill an important niche in the midst of shifting federal government policies.
The company may have anticipated that opportunity when it raised full-year 2025 guidance in the latest earnings report. Another driver of this optimism is likely NeoGenomics' recent completion of its purchase of Pathline, which should both broaden its geographical range in the northeastern United States and deepen its portfolio of molecular and hematology-oncology testing services.
Unanimous Buy Ratings, 19% Upside as Data Center Boom and Fuels Backlog Surge
Mechanical and electrical services provider Comfort Systems USA Inc. (NYSE: FIX) has a unanimous Buy rating from all five analysts reviewing the firm, plus 19% upside potential based on a consensus price target of $517.60. The company's shares have shot upwards in the last month, climbing by about 40%.
Comfort Systems has seen its backlog blossom in recent quarters thanks to the CHIPS Act and major spending pushes on data centers, a key focus of its operations. This shows no signs of slowing in the Trump administration, as the company's backlog grew by almost $1 billion from the end of 2024 to the conclusion of this year's first quarter.
With anticipated revenue growth for 2025 in the double digits, Comfort Systems could get a further boost if the administration's efforts to restore manufacturing operations to the United States are successful.
MarketBeat Media, LLC dba TickerReport
345 N Reid Place, Suite 620, Sioux Falls, SD 57103.